TriaGen Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
EP
TriaGen Wealth Management's ARKG Position: Q3 2021 in Review
TriaGen Wealth Management sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2021, closing a stake of 12,411 shares — an estimated $1.05M sold.
TriaGen Wealth Management first reported a position in ARKG in Q4 2020 and held it in 3 quarters. The position peaked at $1.1M in Q1 2021. 468 funds tracked by Wall St. Rank hold ARKG as of Q3 2021.
- TriaGen Wealth Management reported no remaining ARK Genomic Revolution ETF position as of Q3 2021 after selling out during the quarter.
- TriaGen Wealth Management sold 12,411 ARK Genomic Revolution ETF shares in Q3 2021, an estimated $1.05M.
- TriaGen Wealth Management first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 3 quarters.
- TriaGen Wealth Management's ARK Genomic Revolution ETF position peaked at $1.1M in Q1 2021.
- 468 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2021.
Based on TriaGen Wealth Management's 13F filing for Q3 2021, filed 10 Nov 2021.